logo-loader

Poolbeg Pharma Driving forward R&D programmes while seeking partners

Last updated: 07:25 02 Nov 2023 GMT, First published: 07:23 02 Nov 2023 GMT

Poolbeg Pharma continues to advance its lead programmes and has struck a collaboration that may lead to its first out-licensing deal. The company is also continuing its campaign to find a partner and effectively monetise its phase II-ready lead compound POLB 001, which they are expanding into oncology, while progressing its other assets towards the clinic.

In recent months, Poolbeg has established an initial partnership for its exclusively licensed oral drug delivery technology, strengthened the patent protection on POLB-001, obtained the initial outputs from its influzenza AI-based drug discovery programme and commenced lab-based validation of drug targets identified during its RSV AI programme.

Poolbeg has formed a collaboration with an undisclosed Nasdaq-listed biopharma company to evaluate a drug formulation using its oral drug delivery technology. The aim is to optimise the delivery of the partner company's novel drug to its target location for use in a metabolic condition, with the hope that this could improve efficacy and potentially value. Management hopes this will develop into a full licensing agreement, which could potentially generate some early revenue.

This partnership reflects recognition of the oral delivery technology's benefits and management expects that it could lead to other similar arrangements in the future, given the broad applicability of the technology particularly in metabolic disease. Poolbeg is already evaluating the technology for the oral delivery of a glucon-like peptide 1 (GLP-1) agonist, which we presume to be liraglutide. This product is approved as an injectable for obesity and diabetes.

A proof of technology study on this product is due to commence in H1 2024, after which Poolbeg may try to find a licensing partner. The global GLP-1 market has been predicted to rise rapidly to c.$70bln by 2032. Although there are a number of oral formulations of GLP-1 agonists in clinical development, including with liraglutide, Poolbeg believes it can achieve higher oral bioavailability with its technology.

Poolbeg is progressing towards validation of the outputs from its AI-led programme with CytoReason. This programme combined Poolbeg's influenza disease progression data from human challenge trials with CytoReason's AI-led platform and has enabled the identification of a number of novel drug targets for influenza. The company's Scientific Advisory Board recently reviewed the outputs from the programme and reached a consensus on the prioritisation of novel drug targets to bring forward to validation. This is due to be completed in 2024, and Poolbeg is continuing to discuss the outputs from this programme with prospective partners.

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Gelion, Bango, Poolbeg Pharma, Georgina Energy, Kenmare Resources - Small...

Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has secured an evaluation deal with a top-15 global automaker for its sulfur battery cathode tech. It's now working with several major OEMs on EV applications. Read more  Bango PLC (AIM:BGO, OTCQX:BGOPF) has been selected by South Korean telecoms...

on 6/10/26